Jason M. Hafron, MD, presented “Implementing Changes in Patient Behavior” during the 34th International Prostate Cancer Update on February 12, 2024, in Vail, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Hafron, Jason M. “Implementing Changes in Patient Behavior.” February 2024. Accessed Nov 2024. https://grandroundsinurology.com/implementing-changes-in-patient-behavior/
Implementing Changes in Patient Behavior – Summary
Jason M. Hafron, MD, provides guidance on implementing changes in ADT patient behavior and motivating compliance with lifestyle adjustments. He begins by reviewing the body composition changes which result from ADT.
Dr. Hafron discusses how these changes in body composition, along with other adverse effects of ADT, led to the creation of the Prostate Cancer 360 (PC36) Working Group. This interdisciplinary group developed monitoring and management recommendations intended to mitigate or prevent ADT-associated adverse events in a PC360 Handbook, which includes pre-ADT counseling on lifestyle changes.
He presents the benefits of different levels of physical exercise for patients on ADT. He examines data demonstrating the impact of standardized exercise on ADT patient QoL, noting that physical exercise has significant benefits.
Dr. Hafron concludes with guidance on patient nutrition. He notes that diet has a significant influence on prostate cancer survival rate, with a typical Western diet significantly increasing the mortality rate for patients on ADT.
About The 34th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 34th iteration of the meeting occurred February 11-14, 2024 in Vail, Colorado. To view more educational presentations from IPCU 34, visit our collection page.
ABOUT THE AUTHOR
Jason M. Hafron, MD, is the Director of Research at the Michigan Institute of Urology, P.C. He is also an Associate Professor of Urology at the William Beaumont School of Medicine at Oakland University in Rochester, Michigan, and the Director of Robotic Surgery at Beaumont Hospital, Royal Oak. Dr. Hafron is experienced in all areas of adult urology, but specializes in the minimally invasive treatment of cancers involving the prostate, kidney, and bladder utilizing laparoscopic and robotic surgery. Dr. Hafron received his BS from the University of Michigan and his MD from Loyola University Chicago-Stritch School of Medicine. Dr. Hafron completed his General Surgery and Urology Residency at the Albert Einstein College of Medicine Montefiore Medical Center in New York City. He continued his training as a Fellow in Advanced Laparoscopic and Robotic Surgery at the Cleveland Clinic Foundation, Glickman Urological and Kidney Institute, in Cleveland, Ohio.
Dr. Hafron has published numerous peer-reviewed articles and has presented his work at national and international meetings. He is the principal investigator for multiple clinical research trials at the Michigan Institute of Urology. He is on the Board of Directors of the United Physicians Organization, and has been certified in urology by the American Board of Urology.
